Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Can the Breast Cancer Targeted Drug Trastuzumab Be Given Under the Skin Instead of Intravenously?

Can the Breast Cancer Targeted Drug Trastuzumab Be Given Under the Skin Instead of Intravenously?

Trastuzumab (brand name Herceptin) is standard postoperative preventive (adjuvant) treatment for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, routinely given by intravenous infusion. A new clinical trial, SafeHer, including 2573 patients assessed tolerability and safety of giving trastuzumab, also known as targeted breast cancer therapy, as an injection under the skin rather than an intravenous infusion.

What is human epidermal growth factor receptor (HER2) positivity?

The HER2 receptor mediates cell growth signals. In HER2 + tumors, cancer cells overproduce this receptor, causing more aggressive behavior. Before next-generation drugs targeting the HER2 receptor, such as Herceptin, were developed, HER2 positivity was associated with poorer outcomes and more frequent recurrence. These drugs have greatly improved control of HER2-positive breast cancers. Around 20% of breast cancers are HER2-positive.

- Related topic: Growth factors and cancer

Patients operated on for early-stage breast cancer (up to stage 3) received treatment every 3 weeks for 18 cycles at a fixed 600 mg dose of subcutaneous Herceptin to reduce recurrence risk.

Study results

  • Among 2573 patients, 2282, or approximately 88%, experienced side effects of varying severity.
  • However, only 5% discontinued the drug because of side effects.
  • Serious cardiac side effects (grade 3 or higher) occurred in 24 patients (0.9%). 
  • As expected, side effects were more frequent when chemotherapy accompanied the targeted drug.

In conclusion,

SafeHer confirmed that a fixed 600 mg dose of subcutaneous Herceptin (over 1 year, every 3 weeks for 18 cycles) is safe and tolerable as postoperative preventive (adjuvant) treatment for HER2-positive early breast cancer. These results show similar safety and side-effect profiles for intravenous and subcutaneous forms. If subcutaneous Herceptin is approved, thousands of patients worldwide are expected no longer to need hospital visits at intervals throughout 1 year for its administration.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Can the Breast Cancer Targeted Drug Trastuzumab Be Given Under the Skin Instead of Intravenously?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy